The B-Cell Leukemia drugs in development market research report provides comprehensive information on the therapeutics under development for B-Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for B-Cell Leukemia. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights B-Cell Leukemia - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for B-Cell Leukemia and features dormant and discontinued products.

GlobalData tracks 92 drugs in development for B-Cell Leukemia by 81 companies/universities/institutes. The top development phase for B-Cell Leukemia is phase ii with 36 drugs in that stage. The B-Cell Leukemia pipeline has 65 drugs in development by companies and 27 by universities/ institutes. Some of the companies in the B-Cell Leukemia pipeline products market are: F. Hoffmann-La Roche, Bristol-Myers Squibb and Novartis.

The key targets in the B-Cell Leukemia pipeline products market include Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), B Cell Receptor CD22 (B Lymphocyte Cell Adhesion Molecule or Sialic Acid Binding Ig Like Lectin 2 or T Cell Surface Antigen Leu 14 or CD22), and B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19).

The key mechanisms of action in the B-Cell Leukemia pipeline product include Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19) with 37 drugs in Phase III. The B-Cell Leukemia pipeline products include six routes of administration with the top ROA being Intravenous and ten key molecule types in the B-Cell Leukemia pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.

B-Cell Leukemia overview

B-cell leukemia is a type of blood cancer that originates in the bone marrow, affecting B lymphocytes (B cells), a crucial component of the immune system. This leukemia results in the uncontrolled growth and accumulation of abnormal B cells, which hinder the normal production of healthy blood cells. Diagnosis involves blood tests, bone marrow biopsies, and imaging scans to identify and classify the type and extent of B-cell leukemia. Treatment strategies vary based on the type, stage, and individual patient factors. Common treatments include chemotherapy, targeted therapy, immunotherapy, and in some cases, stem cell transplantation.

For a complete picture of B-Cell Leukemia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.